Dec 11, 2022

Experimental cancer therapy shows success in more than 70% of patients in global clinical trials

Posted by in category: biotech/medical

A new therapy that makes the immune system kill bone marrow cancer cells was successful in as many as 73% of patients in two clinical trials, according to researchers from The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai.

The therapy, known as a bispecific antibody, binds to both T cells and multiple and directs the T cells— that can be enlisted to fight off diseases—to kill multiple cells. The researchers described this strategy as “bringing your army right to the enemy.”

The success of the off-the-shelf immunotherapy, called talquetamab, was even seen in patients whose was resistant to all approved multiple myeloma therapies. It uses a different target than other approved therapies: a receptor expressed on the surface of cancer cells known as GPRC5D.

Comments are closed.